<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02987660</url>
  </required_header>
  <id_info>
    <org_study_id>RFL605-P001</org_study_id>
    <nct_id>NCT02987660</nct_id>
  </id_info>
  <brief_title>Comparison of Topography Guided LASIK With WaveLight® EX500 to SMILE With Zeiss VisuMax</brief_title>
  <official_title>Comparison of Topography Guided LASIK With WaveLight® EX500 to SMILE With Zeiss VisuMax</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon, a Novartis Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare Topography Guided Laser In Situ Keratomileusis
      (LASIK) corneal surgery to Small Incision Lenticule Extraction (SMILE) corneal surgery for
      the treatment of myopia with astigmatism.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    management decision with no risk to patient safety
  </why_stopped>
  <start_date type="Actual">March 3, 2017</start_date>
  <completion_date type="Actual">July 26, 2017</completion_date>
  <primary_completion_date type="Actual">July 26, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of eyes with manifest refraction cylinder less than or equal to 0.5 diopter (D) at 3 months</measure>
    <time_frame>Month 3</time_frame>
    <description>Manifest refraction cylinder will be measured monocularly (each eye separately) at 3 or 4 meters (m) under photopic lighting conditions using a phoropter and Early Treatment Diabetic Retinopathy Study (ETDRS) chart. The manifest refraction at 4 m or 3 m will be adjusted for optical infinity by adding - 0.25 D to the sphere value.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean manifest refraction cylinder at 3 months</measure>
    <time_frame>Month 3</time_frame>
    <description>Manifest refraction cylinder will be measured monocularly at 3 or 4 meters under photopic lighting conditions using a phoropter and ETDRS chart. The manifest refraction at 4 m or 3 m will be adjusted for optical infinity by adding - 0.25 D to the sphere value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Uncorrected Visual Acuity (UCVA) at 3 months</measure>
    <time_frame>Month 3</time_frame>
    <description>Uncorrected (without spectacles or other visual corrective devices) Visual Acuity (UCVA) testing to be done monocularly in photopic conditions without glare at 3 or 4 meters. Visual Acuity (VA) is measured in &quot;logarithm of the minimum angle of resolution&quot; (logMAR). A lower logMAR value indicates better visual acuity. The Precision Vision illuminator cabinets and ETDRS charts will be used. For subjects who cannot read English letters, a numerical, Tumbling E logMAR chart can be used.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Myopia</condition>
  <condition>Astigmatism</condition>
  <arm_group>
    <arm_group_label>LASIK with EX500</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topography Guided LASIK with WaveLight EX500 excimer laser system in bilateral surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SMILE with VisuMax</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Small incision lenticular extraction (SMILE) with VisuMax laser in bilateral surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Topography Guided LASIK</intervention_name>
    <description>Corneal surgery for refractive error correction</description>
    <arm_group_label>LASIK with EX500</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Small Incision Lenticular Extraction</intervention_name>
    <description>Refractive surgical procedure for the correction of myopia with or without astigmatism</description>
    <arm_group_label>SMILE with VisuMax</arm_group_label>
    <other_name>SMILE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>WaveLight EX500 Excimer Laser System</intervention_name>
    <description>As used for corneal stroma ablation (refractive error correction). The treatment is intended to last the subject's lifetime.</description>
    <arm_group_label>LASIK with EX500</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VisuMax Surgical Laser</intervention_name>
    <description>As used for lenticule creation/removal (refractive error correction). The treatment is intended to last the subject's lifetime.</description>
    <arm_group_label>SMILE with VisuMax</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects in Singapore must be 21 years of age or older and subjects in Korea must be
             upon completion of 19 years of age or older due to local regulations;

          -  Able to comprehend and sign an informed consent form;

          -  Willing and able to complete all postoperative visits;

          -  Myopia requiring optical infinity adjusted refractive error correction of -0.5 to -8.0
             D cylinder and at least 0.75 D of corneal astigmatism;

          -  Intended treatment targeted for emmetropia;

          -  Preoperative best-corrected visual acuity (BCVA) of 0 logMAR or better;

          -  Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Pregnant or lactating, current or planned, during the course of the study;

          -  Dry eye;

          -  Corneal disease;

          -  Diagnosis of advanced glaucoma;

          -  Uncontrolled diabetes;

          -  Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alcon, A Novartis Division</last_name>
    <role>Study Director</role>
    <affiliation>Alcon, A Novartis Division</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2016</study_first_submitted>
  <study_first_submitted_qc>December 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2016</study_first_posted>
  <last_update_submitted>August 15, 2017</last_update_submitted>
  <last_update_submitted_qc>August 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Astigmatism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

